Copper, collagen and pigment
Two very different research threads sit under this heading. The first is dermatological: a copper-binding tripeptide that has been studied since the 1970s in the context of wound healing and extracellular matrix turnover. That literature is genuinely substantial and predates the current peptide market by decades.
The second concerns melanocortin receptors and pigmentation. It is a much shorter literature, and it is the one where several European regulators have published safety notices. We link to those notices rather than summarising them, because the wording matters.
Treating those two threads as one subject, which most supplier pages do, obscures the fact that one is well documented and the other carries active regulatory attention.
As a search term, peptides for skin returns both bodies of work at once, and they have almost nothing in common beyond the organ they concern. Reading them as one subject is how a finding published decades ago in a wound-healing context ends up quoted in support of a compound it was never about. The copper side is easiest to survey directly through a PubMed search on copper peptides and skin.
What is being investigated- Copper binding and extracellular matrix turnover
- Fibroblast activity and collagen synthesis in vitro
- Melanocortin receptor signalling and pigmentation
- Published regulatory positions in the EU
Where this sits legally
The copper peptide has decades of dermatological literature and no approval as a medicine. The pigmentation compound has both a shorter literature and published regulatory notices. Those are different situations.
Compounds studied for skin
Three items across two research threads with very different track records.
What the dermatological work was actually measuring
The copper literature runs mostly on fibroblast cultures and on wound models in animals, with endpoints such as matrix components, the rate at which a wound closes and the expression of particular genes. Those are laboratory measures, chosen because they can be counted, and none of them is a statement about how skin looks. Much of that work was framed as healing rather than cosmetics, which is why parts of it overlap with the tissue repair area more closely than with anything sold under a beauty heading.
The preparations differ as well. A large share of the published dermatological work applied material topically in a vehicle designed for that purpose, and exposure by that route is not comparable to anything in this catalogue. What a buyer can check is narrower and considerably more useful: identity and purity are measurable, they are recorded per batch, and the certificate can be requested before payment. When a supplier document looks convincing but cannot be traced back to a production run, the page on spotting a fabricated certificate sets out what to examine first. Handling deserves the same attention here as anywhere else, which is what the storage and shelf-life notes are for.
What the skin page leaves out
No claims about appearance, and no before-and-after anything. The dermatological literature on copper peptides used routes and preparations that differ from what we supply, so comparing across them is already a stretch. For the pigmentation compound we point at the regulators’ own wording instead of writing our own.
The skin reading list, before you order
One long dermatological literature, one set of regulatory notices. Both linked in full.
GHK-Cu
A tripeptide bound to copper, with one of the longest publication trails in the catalogue.
Read CompoundMelanotan 2
Including the safety notices several European regulators have published, quoted in full.
Read CategoryCollagen peptides
A food ingredient rather than research material, and why it sits under different rules entirely.
Read FrameworkResearch use only
What the label permits, what it forbids, and who carries the responsibility.
ReadQuestions about skin research
Mostly about telling the two threads on this page apart.